GET
/v2/reference/news
Stocks News
News articles related to a ticker (with summaries/sentiment where available).
Endpoint Details
| HTTP Method | GET |
|---|---|
| Path | /v2/reference/news |
| Version | v2 |
| Minimum Plan | free |
Query Parameters
| Parameter | Type | Required | Description |
|---|---|---|---|
api_key |
string | Required | Your API key for authentication |
asset_class |
string | Optional | Filter by asset class (stocks, options, forex, crypto) |
locale |
string | Optional | Filter by locale/market (default: us) |
limit |
integer | Optional | Maximum number of results |
cursor |
string | Optional | Pagination cursor for next page |
Example Request
curl "https://mail.tradeiqai.com/api/v2/reference/news?api_key=YOUR_API_KEY"
Note: Replace YOUR_API_KEY with your actual API key.
Response Attributes
| Attribute | Type | Description |
|---|---|---|
ok | boolean | Indicates if the request was successful (e.g., 1) |
data | object | Response data object |
data.status | string | Response status (typically "OK") (e.g., OK) |
data.results | array | Array of 10 items |
| Array items contain: | ||
data.results[].id | string | String value (e.g., f97920925513be162c7678c35b4bef43d2bc644579a2e41dd1...) |
data.results[].publisher | object | |
data.results[].publisher.properties | unknown | |
data.results[].title | string | String value (e.g., Lakefront Announces Sale of Preclinical CAR-T Prog...) |
data.results[].author | string | String value (e.g., Na) |
data.results[].published_utc | string | String value (e.g., 2026-10-14T20:01:00Z) |
data.results[].article_url | string | String value (e.g., https://www.globenewswire.com/news-release/2026/10...) |
data.results[].tickers | array | Array of objects |
data.results[].image_url | string | String value (e.g., https://ml-eu.globenewswire.com/Resource/Download/...) |
data.results[].description | string | String value (e.g., Lakefront Biotherapeutics has completed the sale o...) |
data.results[].keywords | array | Array of objects |
data.results[].insights | array | Array of objects |
| Array items contain: | ||
data.results[].insights[].ticker | string | String value (e.g., LKFT) |
data.results[].insights[].sentiment | string | String value (e.g., positive) |
data.results[].insights[].sentiment_reasoning | string | String value (e.g., The company successfully completed a strategic div...) |
Example Response
{
"ok": true,
"data": {
"status": "OK",
"count": 10,
"results": [
{
"id": "f97920925513be162c7678c35b4bef43d2bc644579a2e41dd1b0aca5c0fa3769",
"publisher": {
"name": "GlobeNewswire Inc.",
"homepage_url": "https://www.globenewswire.com",
"logo_url": "https://s3.massive.com/public/assets/news/logos/globenewswire.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/globenewswire.ico"
},
"title": "Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics",
"author": "Na",
"published_utc": "2026-10-14T20:01:00Z",
"article_url": "https://www.globenewswire.com/news-release/2026/10/14/3381122/0/en/lakefront-announces-sale-of-preclinical-car-t-programs-to-armed-cell-therapeutics.html",
"tickers": [
"LKFT"
],
"image_url": "https://ml-eu.globenewswire.com/Resource/Download/5100317d-9c26-4bbc-9bcc-dd77343f5f96",
"description": "Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics for \u20ac8 million upfront plus up to $230 million in milestone payments and royalties. The sale marks the substantial completion of Lakefront's previously announced wind-down of legacy cell therapy activities, allowing the company to focus on its newly established T-cell engager pipeline while shareholders retain potential upside from future progress.",
"keywords": [
"cell therapy",
"pipeline sale",
"CAR-T therapies",
"strategic alternatives",
"T-cell engagers",
"milestone payments",
"wind-down"
],
"insights": [
{
"ticker": "LKFT",
"sentiment": "positive",
"sentiment_reasoning": "The company successfully completed a strategic divestiture of non-core assets, generating upfront cash (\u20ac8M) with significant milestone potential ($230M), while maintaining royalty upside. This allows refocus on their clinical-stage immunology pipeline and preserves shareholder value through future milestone participation."
}
]
},
{
"id": "9db26ba971721aa84e7d872679a70398a92a0828bf30f3154294c5fe142b5827",
"publisher": {
"name": "GlobeNewswire Inc.",
"homepage_url": "https://www.globenewswire.com",
"logo_url": "https://s3.massive.com/public/assets/news/logos/globenewswire.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/globenewswire.ico"
},
"title": "MannKind to Participate in the Chardan Healthcare Conference",
"author": "Na",
"published_utc": "2026-10-14T20:01:00Z",
"article_url": "https://www.globenewswire.com/news-release/2026/10/14/3381121/29517/en/mannkind-to-participate-in-the-chardan-healthcare-conference.html",
"tickers": [
"MNKD"
],
"image_url": "https://ml.globenewswire.com/Resource/Download/fc4da88e-772c-44f1-87a9-36ece175bc5b",
"description": "MannKind Corporation announced that CEO Michael Castagna will participate in a panel discussion on innovation in chronic respiratory diseases at the Chardan Healthcare Conference on October 20, 2026. The company will also conduct one-on-one investor meetings. MannKind is a biopharmaceutical company focused on cardiometabolic and orphan lung diseases, with treatments addressing diabetes, pulmonary hypertension, and fluid overload conditions.",
"keywords": [
"MannKind Corporation",
"Chardan Healthcare Conference",
"chronic respiratory diseases",
"biopharmaceutical",
"cardiometabolic",
"pulmonary hypertension",
"heart failure",
"chronic kidney disease"
],
"insights": [
{
"ticker": "MNKD",
"sentiment": "positive",
"sentiment_reasoning": "The company is actively participating in industry conferences and presenting on innovation in chronic respiratory diseases, demonstrating engagement with investors and the medical community. The announcement highlights their focus on addressing serious unmet medical needs and their expertise in drug-device combinations, which suggests confidence in their pipeline and market position."
}
]
},
{
"id": "64ab30374bc6974c00820936ffe998aeb225e4504fe868f5bd6636d80959b40b",
"publisher": {
"name": "GlobeNewswire Inc.",
"homepage_url": "https://www.globenewswire.com",
"logo_url": "https://s3.massive.com/public/assets/news/logos/globenewswire.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/globenewswire.ico"
},
"title": "MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026",
"author": "Na",
"published_utc": "2026-10-14T20:01:00Z",
"article_url": "https://www.globenewswire.com/news-release/2026/10/14/3381120/0/en/mimedx-to-host-third-quarter-2026-operating-and-financial-results-conference-call-on-october-28-2026.html",
"tickers": [
"MDXG"
],
"image_url": "https://ml.globenewswire.com/Resource/Download/2a60ab36-4917-479c-b53a-4f2113ca347d",
"description": "MiMedx Group, Inc. announced it will report Q3 2026 financial results on October 28, 2026, followed by a webcast and conference call at 4:30 p.m. ET. The company also announced a favorable federal court ruling vacating FDA determinations regarding AXIOFILL's regulatory classification as a biological product.",
"keywords": [
"Q3 2026 earnings",
"conference call",
"AXIOFILL",
"FDA regulatory classification",
"federal court ruling",
"wound care",
"biological product"
],
"insights": [
{
"ticker": "MDXG",
"sentiment": "positive",
"sentiment_reasoning": "The company received a favorable federal court ruling vacating FDA determinations against AXIOFILL's classification, which removes regulatory obstacles and supports the company's product positioning. This is a significant legal victory that could positively impact the company's business operations and product commercialization."
}
]
},
{
"id": "3b37b8108cff88e840b24f489d4a17a6db722cc82cce80affa4573625fc95d1a",
"publisher": {
"name": "GlobeNewswire Inc.",
"homepage_url": "https://www.globenewswire.com",
"logo_url": "https://s3.massive.com/public/assets/news/logos/globenewswire.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/globenewswire.ico"
},
"title": "Lakefront kondigt de verkoop aan van haar preklinische CAR-T-programma\u2019s aan Armed Cell Therapeutics",
"author": "Na",
"published_utc": "2026-10-14T20:01:00Z",
"article_url": "https://www.globenewswire.com/news-release/2026/10/14/3381122/0/nl/lakefront-kondigt-de-verkoop-aan-van-haar-preklinische-car-t-programma-s-aan-armed-cell-therapeutics.html",
"tickers": [
"LKFT"
],
"image_url": "https://ml-eu.globenewswire.com/Resource/Download/5100317d-9c26-4bbc-9bcc-dd77343f5f96",
"description": "Lakefront Biotherapeutics has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV for an \u20ac8 million upfront payment plus up to $230 million in milestone payments and royalties. The transaction marks the near-completion of Lakefront's previously announced wind-down of cell therapy activities, allowing the company to focus on its T-cell engager pipeline while providing shareholders potential upside from Armed Cell's future progress.",
"keywords": [
"cell therapy",
"pipeline sale",
"CAR-T therapies",
"strategic restructuring",
"milestone payments",
"T-cell engagers",
"biotechnology"
],
"insights": [
{
"ticker": "LKFT",
"sentiment": "positive",
"sentiment_reasoning": "The company successfully completed a strategic divestiture, monetizing early-stage assets while maintaining upside through milestone payments and royalties. This allows Lakefront to focus on its more promising T-cell engager pipeline and maintain a strong cash position, demonstrating effective capital allocation and strategic clarity."
}
]
},
{
"id": "31e93002ed502dc625b039a75b9cc4bae09cc086aa13a004da8fbc3dd81bceba",
"publisher": {
"name": "GlobeNewswire Inc.",
"homepage_url": "https://www.globenewswire.com",
"logo_url": "https://s3.massive.com/public/assets/news/logos/globenewswire.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/globenewswire.ico"
},
"title": "Leonardo DRS Expands Federal Access to Mission-Critical Technologies Through NASA SEWP VI",
"author": "Na",
"published_utc": "2026-10-14T20:00:00Z",
"article_url": "https://www.globenewswire.com/news-release/2026/10/14/3381115/0/en/leonardo-drs-expands-federal-access-to-mission-critical-technologies-through-nasa-sewp-vi.html",
"tickers": [
"DRS"
],
"image_url": "https://ml.globenewswire.com/Resource/Download/923b4871-2baf-4a3f-a390-6844426a4560",
"description": "Leonardo DRS has been awarded a 10-year prime contract under NASA's Solutions for Enterprise-Wide Procurement (SEWP) VI Program, extending through 2036. The government-wide acquisition contract provides federal agencies streamlined access to DRS products and services. DRS has held the SEWP prime contractor position since 2015 and has already generated over $110 million in procurements under SEWP V, with an 'Excellent' performance rating from NASA.",
"keywords": [
"government contract",
"SEWP VI",
"federal procurement",
"defense technology",
"10-year contract",
"NASA",
"national security"
],
"insights": [
{
"ticker": "DRS",
"sentiment": "positive",
"sentiment_reasoning": "The company secured a significant 10-year government contract extension worth an indefinite amount with proven track record ($110M+ under previous contract), excellent NASA performance rating, and expanded product offerings across 368 contract line items. This represents business continuity and growth opportunity through 2036."
}
]
},
{
"id": "90f04761148e9b042614d03b7d6330175124329c35a1e7d430f5f8ab2fea46df",
"publisher": {
"name": "The Motley Fool",
"homepage_url": "https://www.fool.com/",
"logo_url": "https://s3.massive.com/public/assets/news/logos/themotleyfool.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico"
},
"title": "What $10,000 Invested in SpaceX Today Could Be Worth by the End of 2027",
"author": "Jack Delaney",
"published_utc": "2026-10-14T19:39:00Z",
"article_url": "https://www.fool.com/investing/2026/10/14/what-10000-invested-in-spacex-today-could-be-worth/?source=iedfolrf0000001",
"tickers": [
"SPCX",
"GOOG",
"GOOGL",
"GOOGM",
"GOOGN"
],
"image_url": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F890648%2Fspcx.png&w=1200&op=resize",
"description": "SpaceX, which went public in June 2026, shows mixed investment potential by end of 2027. Analysts are generally bullish with a median price target of $217 (implying 33% upside from $163.42), but the lowest target is just $75. The company demonstrated 92% revenue growth to $7.8 billion in Q2 2026 but remains unprofitable with heavy capital expenditures of $18.4 billion. Success depends on execution of AI data center satellites and other growth initiatives.",
"keywords": [
"SpaceX IPO",
"price targets",
"revenue growth",
"AI compute capacity",
"profitability concerns",
"capital expenditures",
"long-term investment"
],
"insights": [
{
"ticker": "SPCX",
"sentiment": "positive",
"sentiment_reasoning": "76% of 46 analysts rate it a buy with median price target of $217 (33% upside). Strong 92% revenue growth and expanding AI/connectivity divisions support bullish outlook. However, sentiment is tempered by unprofitability, high capex spending, and execution risks, preventing a strongly positive rating."
},
{
"ticker": "GOOG",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a cloud deal partner with SpaceX worth up to $26 billion annually (combined with Anthropic deal). This represents a business opportunity but is not the primary focus of the article."
},
{
"ticker": "GOOGL",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a cloud deal partner with SpaceX worth up to $26 billion annually (combined with Anthropic deal). This represents a business opportunity but is not the primary focus of the article."
},
{
"ticker": "GOOGM",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a cloud deal partner with SpaceX worth up to $26 billion annually (combined with Anthropic deal). This represents a business opportunity but is not the primary focus of the article."
},
{
"ticker": "GOOGN",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a cloud deal partner with SpaceX worth up to $26 billion annually (combined with Anthropic deal). This represents a business opportunity but is not the primary focus of the article."
}
]
},
{
"id": "69f16453c1594e763052e4ff828c00b5e3c2b796075c91d5c0fd3aa4cf2cbda7",
"publisher": {
"name": "The Motley Fool",
"homepage_url": "https://www.fool.com/",
"logo_url": "https://s3.massive.com/public/assets/news/logos/themotleyfool.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico"
},
"title": "Why Arm Holdings Stock Was Falling Today",
"author": "Jeremy Bowman",
"published_utc": "2026-10-14T19:32:27Z",
"article_url": "https://www.fool.com/investing/2026/10/14/why-arm-holdings-stock-was-falling-today/?source=iedfolrf0000001",
"tickers": [
"ARM"
],
"image_url": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2Ff0c2c2e0351472dd88dcceea09d015afd5243375-1200x800.png%3Fw%3D800%26q%3D75%26fit%3Dmax%26auto%3Dformat&w=1200&op=resize",
"description": "Arm Holdings stock fell 6.7% following a hotter-than-expected September CPI report (3.7% vs. 3.6% expected), which increased expectations of a Fed interest rate hike. As a growth stock with valuations heavily dependent on future earnings, Arm is particularly sensitive to interest rate changes. Higher rates reduce the present value of future cash flows, pressuring the stock price.",
"keywords": [
"CPI",
"interest rates",
"Fed policy",
"tech stocks",
"valuation",
"inflation",
"semiconductor stocks"
],
"insights": [
{
"ticker": "ARM",
"sentiment": "negative",
"sentiment_reasoning": "Stock declined 6.7% due to higher-than-expected CPI data increasing the likelihood of Fed rate hikes. Arm's valuation is particularly vulnerable to rising interest rates since most of its value derives from earnings projected years into the future, making the discount rate impact more pronounced."
}
]
},
{
"id": "e9377becb1c9a23912e0edf683c9463fdd485dd18a5c3499313f7acc22d59870",
"publisher": {
"name": "The Motley Fool",
"homepage_url": "https://www.fool.com/",
"logo_url": "https://s3.massive.com/public/assets/news/logos/themotleyfool.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico"
},
"title": "Over 25% of the Stocks in the S&P 500 Are Down 40% or More. 4 Bargain Tech Stocks to Buy Now",
"author": "Geoffrey Seiler",
"published_utc": "2026-10-14T19:30:00Z",
"article_url": "https://www.fool.com/investing/2026/10/14/over-25-stocks-sp-500-down-bargain-tech-buy/?source=iedfolrf0000001",
"tickers": [
"NFLX",
"ORCL",
"ORCLpD",
"NOW",
"APP",
"U"
],
"image_url": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F890836%2Fgettyimages-1394998866.jpg&w=1200&op=resize",
"description": "With over 25% of S&P 500 stocks down 40% or more from their highs, the article identifies four undervalued tech stocks as bargain opportunities: Netflix benefits from recession-resistant streaming and advertising growth; Oracle offers leveraged exposure to cloud computing with a massive backlog; ServiceNow is well-positioned for agentic AI orchestration; and AppLovin trades at a cheap valuation with strong revenue and earnings growth.",
"keywords": [
"bargain stocks",
"tech stocks",
"S&P 500",
"cloud computing",
"artificial intelligence",
"SaaS",
"undervalued"
],
"insights": [
{
"ticker": "NFLX",
"sentiment": "positive",
"sentiment_reasoning": "Stock is down significantly but company shows recession-resistant business model, strong advertising growth potential, pricing power, and attractive forward P/E of 18.5x with continued subscriber growth opportunities."
},
{
"ticker": "ORCL",
"sentiment": "positive",
"sentiment_reasoning": "Major growth in cloud computing infrastructure with $664 billion backlog; beaten-down stock price offers upside potential despite high leverage and cash burn concerns; strong cloud computing economics with quick paybacks."
},
{
"ticker": "ORCLpD",
"sentiment": "positive",
"sentiment_reasoning": "Major growth in cloud computing infrastructure with $664 billion backlog; beaten-down stock price offers upside potential despite high leverage and cash burn concerns; strong cloud computing economics with quick paybacks."
},
{
"ticker": "NOW",
"sentiment": "positive",
"sentiment_reasoning": "Deeply embedded software platform well-positioned for agentic AI era; attractive forward P/S multiple of 7.5x; positioned as likely leader in AI Control Tower orchestration space with significant growth opportunity."
},
{
"ticker": "APP",
"sentiment": "positive",
"sentiment_reasoning": "Trading at rock-bottom valuation of 13x 2027 earnings; strong growth metrics with 53% revenue growth and 66% EPS surge; expanding into consumer vertical with positive analyst indicators for future growth."
},
{
"ticker": "U",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as increased competition to AppLovin in gaming ad space, but no direct investment recommendation or detailed analysis provided."
}
]
},
{
"id": "5119d291fac19a0127e199b2aab0e7ad679e1d25ec06b38d1615200cb4e2e88c",
"publisher": {
"name": "The Motley Fool",
"homepage_url": "https://www.fool.com/",
"logo_url": "https://s3.massive.com/public/assets/news/logos/themotleyfool.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico"
},
"title": "IonQ vs. Nebius Group: Which Technology Stock Is a Better Buy in 2026?",
"author": "Sara Appino",
"published_utc": "2026-10-14T19:20:05Z",
"article_url": "https://www.fool.com/coverage/better-buy/2026/10/14/ionq-vs-nebius-group-which-technology-stock-is-a-better-buy-in-2026/?source=iedfolrf0000001",
"tickers": [
"IONQ",
"NBIS",
"AMZN",
"MSFT",
"NVDA",
"GOOG",
"GOOGL",
"GOOGM",
"GOOGN"
],
"image_url": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F4d7cf8a88a5640810adcc0a8bcd10ea8cade7192-1200x800.jpg%3Fw%3D800%26q%3D75%26fit%3Dmax%26auto%3Dformat&w=1200&op=resize",
"description": "The article compares two high-growth technology stocks: IonQ, which develops quantum computing hardware with 202% revenue growth but significant losses, and Nebius Group, an AI cloud infrastructure provider with 479% revenue growth and positive profitability. The author recommends Nebius as the better buy in 2026, citing its current profitability, extraordinary growth, and strong market demand, while acknowledging IonQ's long-term potential in quantum computing.",
"keywords": [
"quantum computing",
"AI cloud infrastructure",
"revenue growth",
"profitability",
"high-performance computing",
"data centers",
"technology stocks"
],
"insights": [
{
"ticker": "IONQ",
"sentiment": "neutral",
"sentiment_reasoning": "IonQ shows impressive 202% revenue growth and strategic partnerships with Amazon and Microsoft, but faces significant challenges including $510.4M net losses, negative free cash flow of $299.6M, and unproven business model. The company has long-term potential but requires patience and carries substantial execution risk."
},
{
"ticker": "NBIS",
"sentiment": "positive",
"sentiment_reasoning": "Nebius demonstrates exceptional 479% revenue growth, achieved profitability with $101.7M net income, positive net margin of 19.2%, and strong market demand for AI infrastructure. The company is generating results now while growing at a remarkable pace, making it the author's recommended choice despite capital-intensive operations and competition from larger incumbents."
},
{
"ticker": "AMZN",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a strategic partner of IonQ providing cloud platform access; no independent analysis provided."
},
{
"ticker": "MSFT",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a strategic partner of IonQ providing cloud platform access; no independent analysis provided."
},
{
"ticker": "NVDA",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a competitor to Nebius and as a significant stakeholder in Nebius; noted as having more resources and established customer base."
},
{
"ticker": "GOOG",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a major incumbent competitor to Nebius with significantly more resources and established customer bases."
},
{
"ticker": "GOOGL",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a major incumbent competitor to Nebius with significantly more resources and established customer bases."
},
{
"ticker": "GOOGM",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a major incumbent competitor to Nebius with significantly more resources and established customer bases."
},
{
"ticker": "GOOGN",
"sentiment": "neutral",
"sentiment_reasoning": "Mentioned as a major incumbent competitor to Nebius with significantly more resources and established customer bases."
}
]
},
{
"id": "8da64af6dc4343bfa9084695b9fd9cc064d78abd5879deca89dea3e51b93481a",
"publisher": {
"name": "The Motley Fool",
"homepage_url": "https://www.fool.com/",
"logo_url": "https://s3.massive.com/public/assets/news/logos/themotleyfool.svg",
"favicon_url": "https://s3.massive.com/public/assets/news/favicons/themotleyfool.ico"
},
"title": "Nvidia Talked Up Generative AI 2 Weeks Before ChatGPT. The Clues Hold Up.",
"author": "Anders Bylund",
"published_utc": "2026-10-14T19:19:02Z",
"article_url": "https://www.fool.com/investing/2026/10/14/nvidia-talked-up-generative-ai-2-weeks-before-chatgpt-the-clues-hold-up/?source=iedfolrf0000001",
"tickers": [
"NVDA",
"MSFT",
"META"
],
"image_url": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fcdn.content.foolcdn.com%2Fimages%2F1umn9qeh%2Fproduction%2F5b2bd89ff15e9502542f199e4ef1de47cfd6f61a-1290x860.png%3Fw%3D800%26q%3D75%26fit%3Dmax%26auto%3Dformat&w=1200&op=resize",
"description": "Nvidia's November 2022 earnings call, two weeks before ChatGPT's release, contained clear signals about the generative AI boom. While the report appeared disappointing on the surface with missed targets and gaming revenue collapse, management specifically highlighted large language models and generative AI as drivers of 31% data center revenue growth. The company was already shipping H100 GPUs for AI workloads, and its systems-level approach to AI infrastructure\u2014including networking and storage\u2014positioned it to capture significant value from the emerging AI wave.",
"keywords": [
"generative AI",
"data center",
"large language models",
"H100 GPU",
"earnings signals",
"AI infrastructure",
"ChatGPT",
"semiconductor"
],
"insights": [
{
"ticker": "NVDA",
"sentiment": "positive",
"sentiment_reasoning": "Despite a disappointing Q3 report, Nvidia demonstrated early leadership in generative AI with growing data center revenue (+31%), shipping of H100 chips, and management's explicit focus on LLMs and generative AI. The company's systems-level approach to AI infrastructure proved prescient, leading to its transformation from $390B to $5.5T market cap."
},
{
"ticker": "MSFT",
"sentiment": "positive",
"sentiment_reasoning": "Microsoft was identified as OpenAI's biggest backer and was launching an AI infrastructure platform running entirely on Nvidia's InfiniBand networking, positioning it as a key beneficiary of the AI boom alongside Nvidia."
},
{
"ticker": "META",
"sentiment": "neutral",
"sentiment_reasoning": "While Nvidia pitched Omniverse for metaverse applications with a $150B market opportunity estimate equal to AI enterprise software, the metaverse ultimately did not capture investor attention as AI did, making this a missed opportunity for Meta."
}
]
}
],
"request_params": {
"ticker": null,
"limit": 10,
"order": "desc",
"sort": "published_utc",
"published_utc.gte": "2026-10-09",
"published_utc.lte": null
}
}
}